NULOJIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NULOJIX (NULOJIX).
Belatacept is a selective T-cell costimulation blocker that binds to CD80 and CD86 on antigen-presenting cells, thereby blocking CD28-mediated costimulation and inhibiting T-cell activation and proliferation.
| Metabolism | Belatacept is a fusion protein that is expected to be degraded into small peptides and amino acids via general protein catabolism; no specific metabolic pathways or CYP enzyme involvement. |
| Excretion | Renal: minimal as intact drug; primarily eliminated via reticuloendothelial system metabolism and proteolysis; <5% excreted unchanged in urine; no significant biliary or fecal elimination. |
| Half-life | Terminal half-life: 8-12 days (mean ~11 days) after IV administration; prolonged due to FcRn-mediated recycling; supports every 2-week dosing. |
| Protein binding | 98% bound to plasma proteins; primarily to beta-2-glycoprotein I and other unidentified proteins. |
| Volume of Distribution | Vd: 0.04-0.06 L/kg; small volume consistent with limited extravascular distribution, primarily confined to vascular space. |
| Bioavailability | IV only: 100% bioavailability; not administered via other routes (no oral or SC formulation). |
| Onset of Action | IV: Maximum immunosuppression achieved within 2-4 weeks after start of therapy; clinical effect on acute rejection prevention evident after first dose but full effect with repeated doses. |
| Duration of Action | Immunosuppressive effect persists for weeks after last dose due to long half-life; dosing interval is 2 weeks; antibody levels decline slowly over months. |
5 mg/kg intravenously on day 1, day 15, day 29, day 43, day 57, then every 4 weeks (monthly) thereafter.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; hemodialysis does not significantly remove belatacept. |
| Liver impairment | No specific dose adjustment for hepatic impairment; pharmacokinetics not studied in moderate to severe hepatic impairment (Child-Pugh B or C). Use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years); no approved dosing. |
| Geriatric use | No specific dose adjustment; select dose with caution due to greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or drug therapy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NULOJIX (NULOJIX).
| Breastfeeding | It is unknown whether belatacept is excreted in human milk. In animal studies, belatacept was detected in the milk of lactating cynomolgus monkeys. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from belatacept, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is not available for humans. |
| Teratogenic Risk | Belatacept (NULOJIX) is classified as Pregnancy Category C. Animal studies with belatacept in cynomolgus monkeys at doses up to 20 mg/kg (approximately 4 times the recommended human dose) showed no evidence of fetal harm or teratogenicity. However, because animal reproduction studies are not always predictive of human response, and immunosuppressive therapies generally carry risks, belatacept should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. No well-controlled studies in pregnant women exist. First trimester risks are largely unknown; second and third trimester exposure may theoretically increase risks of infection and other complications due to maternal immunosuppression. |
■ FDA Black Box Warning
Increased risk of post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system; use only in patients who are Epstein-Barr virus (EBV) seropositive.
| Serious Effects |
EBV seronegative or unknown EBV serostatus; liver transplant recipients; hypersensitivity to belatacept or any components.
| Precautions | Increased risk of PTLD, especially in EBV seronegative patients; progressive multifocal leukoencephalopathy (PML); serious infections including tuberculosis, fungal, and viral infections; cytomegalovirus (CMV) infection; graft thrombosis; malignancies; and contraindication in liver transplant due to increased risk of graft loss and death. |
Loading safety data…
| Fetal Monitoring | Monitor pregnant women receiving belatacept for signs of infections, including opportunistic infections, due to immunosuppression. Assess renal function and blood pressure regularly. Monitor for anemia, neutropenia, and thrombocytopenia via complete blood counts. Due to the risk of progressive multifocal leukoencephalopathy (PML), monitor for any new or worsening neurological symptoms. Serial fetal ultrasound may be considered to assess fetal growth and development, although no specific monitoring protocol exists. |
| Fertility Effects | Belatacept may impair fertility. In animal studies, no adverse effects on male or female fertility were observed in cynomolgus monkeys at doses up to 20 mg/kg. However, immunosuppressive therapies in general can affect reproductive function. The effect on human fertility is unknown. |